Spotlight On... Head of FDA's Veterinary Medicine program moves to greener pastures; ImmuCell waves goodbye to its auditor; U.S. zoos pounce on human health tech for aging animals; and more...

The head of the FDA's Foods and Veterinary Medicine program, Michael Taylor, is leaving the agency in June after more than 5 years in the role. During his time at the FDA, Taylor worked on various animal health initiatives including one focused on eliminating antibiotics that contribute to the proliferation of drug-resistant bacteria. Dr. Stephen Ostroff, the former acting commissioner of the FDA, will step in as Taylor's replacement. More

> ImmuCell ($ICCC) is getting a new auditor after the company's current firm backed out of the job. More

> Zoos and aquariums across the U.S. are using human health-based technology to care for aging animals. Story

> Pet tele-health company Activ4Pets (A4P) has appointed Dory Andraos and Henry Aruca to the company's senior executive leadership team. More

> Nexvet Biopharma ($NVET) completed a pilot study of its pain treatment for osteoarthritis in dogs. Statement

> New research shows how using topical repellent insecticidal products can better protect dogs against heartworm disease. Release

> Animal health testing company Mars Veterinary rolled out a new DNA test for breeders. More

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…